Sennoside A Ameliorates Diabetic Atherosclerosis by Inhibiting OSCP1/ERK1/2 Pathway to Regulate Endothelial DysfunctionOA
Sennoside A Ameliorates Diabetic Atherosclerosis by Inhibiting OSCP1/ERK1/2 Pathway to Regulate Endothelial Dysfunction
LIU Mei-zhi;MA Li;MI Meng;JIANG Ya-ning;WANG Zi-yang;SUN Yong-ning
Department of Cardiology,Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai(200071),ChinaDepartment of Endocrinology,Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai(200071),China||Shaanxi Provincial Traditional Chinese Medicine Hospital,Xi'an(710000),ChinaThe First Clinical Medical College,Shaanxi University of Chinese Medicine,Xi'an(712046),ChinaDepartment of Cardiology,Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai(200071),ChinaDepartment of Cardiology,Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai(200071),ChinaDepartment of Cardiology,Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai(200071),China
sennoside Atype 2 diabetes mellitusatherosclerosisendothelial dysfunctionsorganic solute carrier partner 1
sennoside Atype 2 diabetes mellitusatherosclerosisendothelial dysfunctionsorganic solute carrier partner 1
《中国结合医学杂志（英文版）》 2026 (5)
431-441,11
Supported by the National Natural Science Foundation of China(Nos.82074164,82274295 and 82104649),Shaanxi Province Innovation Capability Support Program Project(Youth Science and Technology New Star,No.2023KJXX-108),and the Shaanxi Provincial Administration of Traditional Chinese Medicine(No.SZY-KJCYC-2023-085)
评论